Key result
MicroRNAs have been proposed as diagnostic and prognostic biomarkers involved in adaptation to changes in the liver microenvironment in patients with hepatic steatosis.
Why the study?
Reliable biomarkers are needed for the adequate diagnosis of non-alcoholic fatty liver, hepatic steatosis, and steatohepatitis.
MicroRNAs are proposed as potential diagnostic and prognostic biomarkers for non-alcoholic fatty liver disease.
Answers are grounded in this paper and cite their sources.
MicroRNAs should not yet guide steatosis diagnosis or prognosis; leaves open need for prospective validation trials.
The obesity pandemic that affects the global population generates one of the most unfavorable microenvironmental conditions in the hepatocyte, which triggers the metabolic hepatopathy known as non-alcoholic fatty liver; its annual rates increase in its prevalence and does not seem to improve in the future. The international consortia, LITMUS by the European Union and NIMBLE by the United States of America, have started a race for the development of hepatic steatosis and steatohepatitis reliable biomarkers to have an adequate diagnosis. MicroRNAs have been proposed as diagnostic and prognostic biomarkers involved in adaptation to changes in the liver microenvironment, which could improve clinical intervention strategies in patients with hepatic steatosis.
No takes yet. Share an insight, caveat, or question.
López-Sánchez et al. (2020) conducted a review in Non-alcoholic fatty liver disease. MicroRNAs was evaluated. MicroRNAs have been proposed as diagnostic and prognostic biomarkers involved in adaptation to changes in the liver microenvironment in patients with hepatic steatosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: